Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment

Estimated Time
30 minutes

Release Date
Nov 29, 2022

Expiration Date
Nov 28, 2023

ACTIVITY DESCRIPTION
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will:
  • Review guideline recommendations for biomarker testing and treatment selection
  • Present clinical evidence for the use of current and emerging targeted therapies
  • Discuss health disparities in biomarker testing

Speakers

Accreditation and Disclosure Information

TARGET AUDIENCE
This CE activity is intended for community-based oncology clinicians including physicians, advanced practice providers (APPs, ie, NPs and PAs), nurses, and pharmacists who provide care for individuals with NSCLC.
 
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
  • Evaluate the clinical implications of guideline recommendations for biomarker testing
  • Assess the pros and cons of DNA-based next-generation sequencing (NGS), RNA-based NGS, and liquid biopsy
  • Plan strategies to address disparities in the application of biomarker testing
  • Use results of biomarker tests to select and predict results of therapy for patients with and without targetable driver mutations
ACCREDITATION, SUPPORT AND CREDIT
Joint Accreditation with Commendation logo
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
 
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hours and 0.16 contact hour in the area of pharmacology.
 
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour
(0.05 CEU) of the Accreditation Council for Pharmacy Education.
 
Universal Activity Number: JA0007322-0000-22-120-H01-P
Type of Activity: Knowledge 
 
AAPA Credit Designation Statement
AAPA
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until November 28, 2023. PAs should only claim credit commensurate with the extent of their participation.
 
Interprofessional Continuing Education (IPCE) Statement
IPCE
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
 
 
 
SUPPORT STATMENT
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Sanofi.
 
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
 
FACULTY DISCLOSURES
Planner/Presenter
Sanjay Juneja ,MD                        
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
 
Advisory Board/Consultant for Daiichi Sankyo and Guardant 360.
Speakers’ Bureau with AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus.
Stock Ownership with Phenomune and xCures.
Independent Contractor for xCures.
 
Planner/Presenter
Lauren Ritterhouse, MD, PhD
Associate Director, Center for Integrated Diagnostics
Assistant Professor, Harvard Medical School
Assistant Pathologist, Massachusetts General Hospital
Boston, MA
 
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Amgen, AstraZeneca, EMD Serono, Merck, Sanofi Genzyme
 
Planner/Presenter
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, MA
 
Advisory Board/Consultant:  AstraZeneca, Bristol Myers Squibb/Novartis, Daiichi Sankyo, NeoGenomics, Pfizer
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Merck, Mirati
 
All of the relevant financial relationships of individuals for this activity have been mitigated.
 
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.
 
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
 
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org
 
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
 
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters
 
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.